Abstract:Protein kinases play important role in the regulation of various biological processes, and their malfunction and dysregulation are intricately linked to the initiation and progression of cancer. The effectiveness of small-molecule kinase inhibitors (KIs) has been well-established in the therapeutic landscape, with the FDA approving over 70 KIs for the treatment of cancer and other diseases. However, the widespread utilization of KIs has been accompanied by reported adverse events, prominently featuring cardiac complications, alongside hepatic and renal function. While many studies have indicated on-target and off-target kinase specificity associated with organ damage, there is an urgent need for building predictive models that can pinpoint which specific kinases might be involved in different types of organ injuries. Such a model would not only facilitate mechanistic elucidation but also serve as a valuable tool for preemptively identifying potential adverse events associated with KI treatment. In this study, we performed polypharmacology-based screening of kinase inhibitors in organotypic tissue slices prepared from the normal heart, liver, and kidney of three distinct species—human, canine, and rodents. These tissue samples were treated individually using a curated selection of 32 KIs that are representative of a larger set of KIs and collectively target most of the 'kinome.' Subsequently, we developed Elastic Net Regularization models by utilizing the kinase inhibition profiles of ~300 kinases. These models were used to predict changes in tissue viability, measured as a percentage change, following the treatment with the respective kinase inhibitors. Using these models, we predicted the toxicity of 428 kinase inhibitors, both as single agents and in pairwise combinations, against three organs—heart, liver, and kidney—in humans, rodents, or canines. Our data show that the models accurately predicted the renal and cardiac toxicity of many FDA-approved KIs that were previously known. For example, the inhibition of RET kinase was identified to be linked with renal toxicity. Further, we compared the toxicity landscape of kinase KIs among different species and identified distinct sets of kinases that were recognized as essential indicators of toxicity within the same organ across species. These disparities underscore the potential distinctions in organ metabolism. In summary, our data provide a comprehensive landscape of kinase inhibitor toxicity. Our models could serve as a valuable resource for predicting kinase inhibitor toxicity across species by leveraging inhibitor profile data. Citation Format: Yuqi Kang, Marina Chan, Songli Zhu, Taranjit S. Gujral. Integrating organotypic tissue slices and polypharmacology-based screening to map the toxicity landscape of kinase inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 616.

Preclinical cardiovascular safety assessment of pharmacology-toxicology relationship for a set of novel kinase inhibitors

A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors

Abstract 616: Integrating organotypic tissue slices and polypharmacology-based screening to map the toxicity landscape of kinase inhibitors

[In vivo integrated safety assessment of the cardiovascular system in drug development]

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies

Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation

Delineating Drug Class and Target-Specific Adverse Events of Kinase Inhibitors

Assessing endothelial cytotoxicity induced by tyrosine kinase inhibitors: insights from Raman and fluorescence imaging

Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data.

Three Tyrosine Kinase Inhibitors Cause Cardiotoxicity by Inducing Endoplasmic Reticulum Stress and Inflammation in Cardiomyocytes

Sunitinib and Imatinib Display Differential Cardiotoxicity in Adult Rat Cardiac Fibroblasts That Involves a Role for Calcium/Calmodulin Dependent Protein Kinase II

In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessment

Kinase Inhibitors FDA-Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities

Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies

Abstract 6295: Role of MAPK11 in the protective mechanisms against toxicity of tyrosine kinase inhibitors

Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo

Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification

Cardiotoxic and Cardioprotective Features of Chronic Β-Adrenergic Signaling

Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors

A Phosphoproteomic Signature in Endothelial Cells Predicts Vascular Toxicity of Tyrosine Kinase Inhibitors Used in CML.